Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2020 · 10-Q
Revenue$43.00K$43.00K+16.7% vs Q2 2019 Net Income-$4.12M-$4.12MN/M vs Q2 2019 EPS Diluted-$0.51-$0.51N/M vs Q2 2019 Operating Income-$4,102,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,291,000N/M Margins · derivedOperating margin-9539.5%+1911.6 pt vs Q2 2019
Net margin-9590.7%+1603.5 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 11, 2020 · 42 d after period end